| pubmed-article:14511423 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C0011860 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C1257987 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C1550594 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C1548760 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C1547300 | lld:lifeskim |
| pubmed-article:14511423 | lifeskim:mentions | umls-concept:C0580822 | lld:lifeskim |
| pubmed-article:14511423 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:14511423 | pubmed:dateCreated | 2003-9-26 | lld:pubmed |
| pubmed-article:14511423 | pubmed:abstractText | Type 2 diabetes is now a global epidemic, with the number of people affected worldwide predicted to more than double to 300 million by the year 2025. While the importance of good glycemic control in countering the microvascular and macrovascular complications of diabetes is widely recognized, monotherapy with sulfonylureas or metformin achieves target blood glucose levels in only a minority of patients. Consequently, there is a pressing need for new treatment strategies that are more effective in providing sustained glycemic control and so reducing the burden of morbidity and mortality associated with diabetes and its complications. There is growing evidence of the benefits of early intervention with aggressive treatment strategies in improving glycemic control and reducing diabetic complications. To provide sustained control, such strategies need to address the combination of insulin resistance and beta-cell dysfunction that underlies most cases of type 2 diabetes. At the same time, treatment needs to address not only glycemic control but also the range of cardiovascular risk factors that are often found clustered together in patients with type 2 diabetes. This paper reviews the rationale and evidence for early combination therapy including a thiazolidinedione in improving glycemic control, and considers the potential for such aggressive therapy in reducing diabetic complications. | lld:pubmed |
| pubmed-article:14511423 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14511423 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14511423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14511423 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14511423 | pubmed:issn | 1520-9156 | lld:pubmed |
| pubmed-article:14511423 | pubmed:author | pubmed-author:GadsbyRogerR | lld:pubmed |
| pubmed-article:14511423 | pubmed:author | pubmed-author:ReuschJane... | lld:pubmed |
| pubmed-article:14511423 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14511423 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:14511423 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14511423 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14511423 | pubmed:pagination | 685-93 | lld:pubmed |
| pubmed-article:14511423 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:meshHeading | pubmed-meshheading:14511423... | lld:pubmed |
| pubmed-article:14511423 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14511423 | pubmed:articleTitle | Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. | lld:pubmed |
| pubmed-article:14511423 | pubmed:affiliation | Denver Research Institute, Denver Veterans Administration Medical Center, Denver, CO, USA. | lld:pubmed |
| pubmed-article:14511423 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14511423 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| pubmed-article:14511423 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:14511423 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
